Content about Wolters Kluwer

December 14, 2012

A new survey by Wolters Kluwer Health indicated that a large majority of consumers think it's a good thing that more individuals are taking a larger and more active role in their own health care.

This should come as no surprise, as recent years have seen tremendous growth in things like electronic personal health records, mobile apps and use of social media. It also ties in with trends in the devolution of health care to the consumer level, such as retail clinics.

A new survey by Wolters Kluwer Health indicated that a large majority of consumers think it's a good thing that more individuals are taking a larger and more active role in their own health care.

This should come as no surprise, as recent years have seen tremendous growth in things like electronic personal health records, mobile apps and use of social media. It also ties in with trends in the devolution of health care to the consumer level, such as retail clinics.

December 13, 2012

According to a new Wolters Kluwer Health survey, 80% of consumers believe the greater "consumerization" of health care — or the trend of individuals taking a greater and more active role in their own health care — is positive for Americans.

PHILADELPHIA — According to a new Wolters Kluwer Health survey, 80% of consumers believe the greater "consumerization" of health care — or the trend of individuals taking a greater and more active role in their own health care — is positive for Americans. Survey data suggests many Americans feel that a greater role in their care is not only good, but necessary, with 86% of consumers reporting that they feel they have to take a more proactive role in managing their own health care in order to ensure better quality of care.

October 19, 2012

A division of Wolters Kluwer Health has released a new version of a Web-based quality-assurance software for pharmacy compounding.

BELLEVUE, Wash. — A division of Wolters Kluwer Health has released a new version of a Web-based quality-assurance software for pharmacy compounding.

Pharmacy OneSource announced the release of a new version of Simplifi 797, used for ensuring compliance with USP chapter 797 regulations, which call for proper training of staff who prepare sterile compounded products.

May 17, 2012

Wolters Kluwer Health has introduced what it called the first mobile application for the Nursing Drug Handbook, the company said Thursday.

AMBLER, Pa. — Wolters Kluwer Health has introduced what it called the first mobile application for the Nursing Drug Handbook, the company said Thursday.

Published by Lippincott Williams & Wilkins, the app is available for Apple and Android devices and is a mobile version of the popular reference for nurses that includes weekly updates.

February 14, 2012

Perrigo on Tuesday announced that it has begun shipping Loratadine-D 12-hour extended-release tablets.

ALLEGAN, Mich. — Perrigo on Tuesday announced that it has begun shipping Loratadine-D 12-hour extended-release tablets.

September 22, 2011

Wolters Kluwer Pharma Solutions has appointed a new VP marketing for its healthcare analytics business.

PHOENIX — Wolters Kluwer Pharma Solutions has appointed a new VP marketing for its healthcare analytics business.

Jack Bush, a 25-year industry veteran, will be responsible for all aspects of marketing strategy and management for the healthcare analytics business, including marketing communications, product forecasting, sales support and government affairs. This is a newly created role at the company, Wolters Kluwer Pharma Solutions said.

September 12, 2011

Healthcare information provider Wolters Kluwer Pharma has appointed Henry Prolog as its VP data strategy, acquisitions and services, the company said.

PHOENIX — Healthcare information provider Wolters Kluwer Pharma has appointed Henry Prolog as its VP data strategy, acquisitions and services, the company said.

The company said Prolog brought more than 25 years of sales, data contracts and marketing experience in the healthcare, technology and information services industries. Before Wolters Kluwer, Prolog worked for IMS Health, Siemens Medical, Fresenius USA and Verispan. Most recently, he was national director for channels at US Oncology in Houston.

July 27, 2011

Wolters Kluwer will sell its pharma-related business, the market research firm said Wednesday.

ALPHEN AAN DEN RIJN, Netherlands — Wolters Kluwer will sell its pharma-related business, the market research firm said Wednesday.

The company’s pharmacy business, which includes the brands Source and Adis, includes marketing and publications services, business intelligence products and advanced analytical tools and services to life science professionals.

July 21, 2011

The Food and Drug Administration has approved a drug for managing obesity made by Lannett.

PHILADELPHIA — The Food and Drug Administration has approved a drug for managing obesity made by Lannett.

Lannett announced the approval of phentermine hydrochloride capsules in the 37.5-mg strength, a generic version of Teva’s Adipex-P.

Phentermine hydrochloride capsules in the 37.5-mg strength had sales of about $8.8 million during the 12-month period ended in May, according to Wolters Kluwer.

June 30, 2011

Impax Labs has agreed not to market a generic version of a drug designed to reduce blood sugar and cholesterol in tablet form until 2015.

HAYWARD, Calif. — Impax Labs has agreed not to market a generic version of a drug designed to reduce blood sugar and cholesterol in tablet form until 2015.

April 27, 2011

Market research firm Wolters Kluwer Health will acquire drug information provider Lexi-Comp, Wolters Kluwer said Wednesday. Financial terms of the deal were not disclosed.

PHILADELPHIA — Market research firm Wolters Kluwer Health will acquire drug information provider Lexi-Comp, Wolters Kluwer said Wednesday. Financial terms of the deal were not disclosed.

April 11, 2011

Another generic drug maker is seeking to market its version of a popular opioid painkiller.

HAYWARD, Calif. — Another generic drug maker is seeking to market its version of a popular opioid painkiller.

Impax said it had filed applications with the Food and Drug Administration seeking approval for a generic version of Purdue Pharma’s Oxycontin (oxycodone) controlled-release tablets in the 10-, 15-, 20-, 30-, 40-, 60- and 80-mg strengths.

Purdue filed suit against Impax on April 8 in the U.S. District Courts for the Southern District of New York, seeking to prevent Impax from marketing its version before the expiration of Purdue's patents.

March 4, 2011

SUPPLIER NEWS — Impax Labs received regulatory approval from the Food and Drug Administration for its generic version of a bacterial infection treatment. The drug maker said the FDA approved its 150-mg doxycycline monohydrate capsules, a drug used to treat bacterial infections and a generic version of Adoxa, made by Nycomed subsidiary PharmaDerm. The 150-mg strength of Adoxa had sales of about $25 million during the 12 months ended in December 2010, according to Wolters Kluwer.

April 1, 2010

Serving as yet another indicator of the important role that retail pharmacists play in the...

WHAT IT MEANS AND WHY IT'S IMPORTANT Serving as yet another indicator of the important role that retail pharmacists play in the U.S. healthcare system is the data conducted by Wolters Kluwer revealing that vaccinations jumped by double-digits this flu season.

(THE NEWS: Flu shot distribution by retail pharmacy increases 36%. For the full story, click here)

March 15, 2010

Patients using commercial health plans in 2009 abandoned their prescriptions at a rate 24% higher...

March 4, 2010

CVS Caremark’s Behavior Change Research Partnership with several leading universities is likely to yield some...

WHAT IT MEANS AND WHY IT'S IMPORTANT CVS Caremark’s Behavior Change Research Partnership with several leading universities is likely to yield some invaluable results for the industry at large because if CVS Caremark executives and the participating academic leaders can better understand customer behavior and develop ways to encourage improved healthy behaviors, then the end result likely will be lower healthcare costs.